A new study shows CDK13 promotes clear cell renal cell carcinoma by enhancing METTL16‑dependent m6A modification of ACLY mRNA, stabilizing and increasing translation of a key metabolic enzyme. The mechanistic chain links a cyclin‑dependent kinase to RNA methylation and metabolic rewiring in renal tumors. Separately, Wang et al. identified UBE2M as a nexus between neddylation and cell‑cycle control in colorectal adenocarcinoma, revealing how protein neddylation enzymes modulate proliferation pathways. Both papers nominate enzymatic nodes (CDK13, METTL16, UBE2M) as candidate therapeutic targets and provide molecular biomarkers for future drug development. Clarification: m6A is a common RNA methylation mark that regulates mRNA stability and translation; neddylation is a ubiquitin‑like protein modification that controls protein activity and turnover.